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ABSTRACT 
Cancer cells contain multiple genetic and epigenetic changes. The relative specificity of many 
epigenetic changes for neoplastic cells has allowed the identification of diagnostic, prognostic 
and predictive biomarkers for a number of solid tumors and hematological malignancies. 
Moreover, epigenetically-acting drugs are already in routine use for cancer and numerous ad-
ditional agents are in clinical trials. Here, we review recent progress in the development and 
application of epigenetic strategies for the diagnosis, risk stratification and treatment of can-
cer.  
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INTRODUCTION 
Despite significant progress in the under-
standing of cancer with the advent of new 
high throughput techniques and the comple-
tion of the human genome project, cancer 
remains a major cause of morbidity and mor-
tality globally (Siegel et al., 2014b; Varmus, 
2010; Venter et al., 2001). Genetic code al-
terations were quickly recognized as signifi-
cant events in tumorigenesis and effort was 
made to develop strategies to better classify, 
risk stratify and ultimately treat cancer. Iden-
tification of several genetic alterations led to 
improved outcomes through the development 
of targeted treatments such as bcr-abl in 
chronic myelogenous leukemia, alk (anaplas-
tic lymphoma kinase) in anaplastic T cell 
lymphoma and lung cancer and BRAFV600E 
in melanoma. Nonetheless, various malig-
nancies continue to have poor outcomes and 
multiple question marks remain regarding 
their underlying pathogenesis. Side by side 
with genomic efforts to understand human 
neoplasia, other alterations of the genetic 
material, that do not affect the DNA se-
quence, but rather its expression were found 
to also play a key role in tumorigenesis. 
These alterations include DNA methylation 
and histone modifications that comprise the 
histone code. The pattern of these chemical 
marks is the epigenome of the cell and the 
term ‘epigenetics’ refers to the study of these 
marks that lead to changes in gene expres-
sion in the absence of corresponding struc-
tural changes in the genome (Lopez et al., 
2009).  
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While it became increasingly recognized 
that cancer is not only a genetic, but also an 
epigenetic disease, new players affecting 
gene expression came onto the scene. Single 
stranded RNAs of ~22 nucleotide in length, 
called microRNAs (miRNAs) can bind to the 
3’ UTR region of various mRNA targets 
down-regulating their expression. More than 
one thousand miRNAs are currently known 
and the list is growing. Each of these has the 
ability to down-regulate the expression of 
potentially thousands of protein coding 
genes (Miranda et al., 2006). Several miR-
NAs were found to be differentially ex-
pressed between normal and cancer tissues 
(Chira et al., 2010). Some of them have been 
shown to act as tumor suppressors and others 
as oncogenes (Esquela-Kerscher and Slack 
2006). Since miRNAs are significant regula-
tors of gene expression, without again alter-
ing the DNA sequence, many researchers 
consider them as another epigenetic mecha-
nism. Moreover, there are data suggesting 
that miRNAs are themselves subject to epi-
genetic transcriptional alterations, while oth-
ers can have a role as chromatin modifiers, 
adding further complexity (Guil and Esteller, 
2009). The study of miRNAs and their in-
volvement in tumorigenesis is an expanding 
and very important field of research that has 
been in the focus of other reviews (Di Leva 
and Croce, 2013). In the current review, 
therefore, we will give an overview of the 
most well studied epigenetic modifications 
and focus on the use of epigenetics in the 
diagnosis, prognosis and treatment of cancer 
but will not further discuss miRNAs. 
 
BASICS IN EPIGENETICS –  
EPIGENETIC MODIFICATIONS 
All cells that constitute an organism con-
tain exactly the same genetic material; how-
ever genes are selectively expressed, depend-
ing on the cell function. Regulation of gene 
expression is partly controlled through alter-
ations of chromatin architecture. Epigenetic 
modifications are therefore essential for reg-
ulation of gene expression and contribute to 
the diversity of phenotypes. In addition, epi-
genetics seems to have a critical regulatory 
role for DNA repair and replication as well, 
acting as a homeostatic system for DNA 
maintenance and function. 
The most well studied epigenetic modifi-
cations in humans are DNA methylation and 
histones modifications. Nucleosome remod-
eling and RNA-mediated targeting are also 
mechanisms of epigenetic regulation. These 
modifications seem to interact with each oth-
er, forming a dynamic epigenetic homeostat-
ic network with many positive and negative 
feedback circuits and the ability to reversibly 
modify the genome. 
 
DNA methylation 
The first described and best-studied epi-
genetic modification is hypermethylation in 
CpG islands of gene promoters. It occurs in 
the 5-carbon of cytosine followed by guanine 
in the CpG islands of gene promoters and 
inactivates transcription by altering the abil-
ity of a gene to interact with transcription 
factors through DNA conformational chang-
es. As an epigenetic modification it is de-
scribed in normal cells in embryogenesis, in 
X-chromosome inactivation, in genomic im-
printing in general, in suppression of repeti-
tive elements and in cancer (Esteller, 2008).  
De novo DNA methylation is catalysed 
by DNA methyltransferases (DNMT) 3A 
and 3B that convert cytosine residues into 5-
methylcytosine (5mC), whereas DNA meth-
ylation is maintained by DNMT1 (Hatzi-
michael and Crook, 2013). Methylated DNA 
provides a docking site for methyl-binding 
proteins (MBD1, MBD2, MBD3 and 
MeCP2), which are recognized by other his-
tone-modifying enzymes, which regulate 
transcription, DNA repair and replication 
(Dawson and Kouzarides, 2012; Klose and 
Bird, 2006). 
DNA methylation was originally thought 
to be permanent, but evolving data show that 
it can be erased or altered as there are en-
zymes, which metabolize 5mC. The ten-
eleven translocation (TET) proteins are hy-
drolases, which oxidise 5mC to 5-hydroxy-
methylcytosine (5hmC) and offer a dynamic 
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potential in epigenetic regulation. 5mC oxi-
dation can lead to DNA demethylation, 
which, beyond its direct effect on gene tran-
scription, can also influence the impact of 
other chromatin modifiers in genome func-
tion (Wu and Zhang, 2011). 
Tumorigenesis is a multistep process and 
it has been shown that the degree of global 
DNA hypomethylation increases as a lesion 
progresses from a benign proliferation of 
cells to an invasive cancer (Ehrlich, 2009; 
Feinberg and Vogelstein, 1983). This phe-
nomenon may contribute to tumorigenesis 
through loss of genetic imprinting, reactiva-
tion of transposable elements and generation 
of chromosomal instability, promoting ge-
netic and epigenetic alterations that lead to 
malignant clone expansion (Esteller, 2008). 
This global hypomethylation is accompanied 
however by hypermethylation of the CpG 
islands of gene promoters of many tumor 
suppressor genes leading to their transcrip-
tional silencing (Easwaran et al., 2010). It 
should also be noted, that hypermethylation 
of the promoters may also silence the ex-
pression of many non-coding RNAs such as 
miRNAs that function as tumor suppressors, 
thus further contributing to tumorigenesis 
(Baylin and Jones, 2011; Lujambio et al., 
2010). 
Recent data show that alterations in DNA 
methylation during tumorigenesis occur not 
only in CpG islands but also in ascending 
and descending segments (“CpG shores”) 
and in the gene bodies as well. Although 
DNA methylation is traditionally associated 
with transcriptional silencing, the effect on 
the DNA templated processes may depend 
on the extent and the spatial distribution of 
the modification and not only on the chemi-
cal type (Baylin and Jones, 2011). 
 
Histone modifications 
Histones are proteins that assemble into a 
protein complex that associates with DNA to 
form a basic structure known as nucleosome. 
A nucleosome is the basic unit of DNA 
packaging within the nucleus and consists of 
147 pairs of genomic DNA that is wrapped 
twice around a highly conserved histone oc-
tamer, consisting of two copies of each of 
the core histones H2A, H2B, H3 and H4. H3 
and H4 are critical regulators of gene repres-
sion and activation and have functions in 
DNA repair. Histone tails undergo many 
post-translational chemical modifications, 
such as acetylation, methylation, phosphory-
lation, sumoylation and ubiquitylation, these 
aminoterminal modifications comprising the 
“histone code”. Based on their function, 
three classes of histone interacting proteins 
have thus far been described: the writers that 
place histone modifications, the erasers that 
remove the histone modifications and, final-
ly, the readers that recognize the histone 
modifications and can deliver nucleosome, 
histone or DNA modifying enzymes 
(Hatzimichael and Crook, 2013). Depending 
on the residue that is modified, the same 
modifications can have opposing effects.  
 
Histone acetylation 
Histone acetylation occurs more often in 
arginine (R) and lysine (K) residues, 
throughout the promoters and the enhancers 
and leads to a more “open” chromatin con-
formation that is transcriptionally active. It is 
a dynamic and reversible modification regu-
lated by the opposite action of two families 
of histone interacting proteins, the histone 
acetyltransferases (HATs) who “write” upon 
the chromatin and the histone deacetylases 
(HDACs) who “erase” the writing, reversing 
its effect on the genome. HATs are subdivid-
ed in two groups: type B and type A (GNAT, 
MYST, CBPtp300). HDACs are subdivided 
into four classes: class I (HDAC 1-3, 8), 
class II (HDAC 4-7, 9, 10), class III (sirtuins 
1-7), class IV (HDAC 11) (Brandl et al., 
2009). 
 
Histone methylation 
Histones can also be methylated at their 
lysine-(K) and arginine-(R) residues. Lysine 
residues can be monomethylated, dimethyl-
ated, or trimethylated whereas arginine resi-
dues can be mono- or dimethylated with 
each modification having a specific biologic 
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effect. Methyl marks are written by S-adeno-
sylmethionine (SAM)-dependent methyl-
transferases and erased by either the Jumonji 
family of demethylases (Tsukada et al., 
2006) or the lysine-specific histone deme-
thylases 1 (LSD1) and 2 (LSD2) (Shi et al., 
2004). All lysine methyltransferases contain 
the conserved SET (Suppressor of variega-
tion, Enhancer of zeste, and Trithorax) do-
main, except for DOT1L (KMT4). DOT1L 
methylates lysine 79 on histone 3 (H3K79) 
and is the only known H3K27 methyltrans-
ferase. 
Histone methylation at lysine and argi-
nine residues does not alter the chromatic 
structure, but rather acts as binding sites for 
other proteins that may condense chromatin 
(Nielsen et al., 2001) or have other effects, 
such as transcription factors toward DNA. 
The different levels of lysine methylation are 
recognized by different methyl-lysine-
binding domains and may be associated with 
either transcription activation or repression. 
H3K4me3, for example promotes transcrip-
tion, whereas H3K27me3 is associated with 
gene silencing (Kouzarides, 2007). Arginine 
methylation of histone proteins has recently 
been shown to antagonize other histone 
marks, further increasing the histone code 
complexity (Guccione et al., 2007). 
Hypermethylation of CpG islands in the 
promoter gene region is associated with a 
particular motif of histone markers: deacety-
lation of H3 and H4, loss of H3K4 tri-
methylation, gain of H3K4 methylation and 
H3K27 trimethylation, modifications which 
synergistically drive the gene into an inacti-
vated form (Jones and Baylin, 2002).  
Global loss of acetylation at H4K16 and 
trimethylation at H4K20 has been described 
as a hallmark of almost all human cancers 
(Fraga et al., 2005), whereas low H3K4me2 
and H3K9ac2 levels have been described in 
breast cancer cells (Elsheikh et al., 2009) and 
low H3K4me2 levels in lung cancer cells 
(Barlesi et al., 2007). Although it is not clear 
whether histone modifications are drivers of 
tumorigenesis or a consequence, increasing 
evidence suggests that imbalance of histone 
modifications is another characteristic of 
cancer. 
 
EPIGENETICS IN DIAGNOSIS 
Identification of novel biomarkers is a 
key objective of cancer research. The relative 
specificity of epigenetic changes for neo-
plasia implies that epigenetics has a key role 
in early diagnosis of cancer and in the dis-
crimination between malignant and pre-
malignant lesions. There is a large volume of 
ongoing research for the identification of di-
agnostic epigenetic biomarkers in various 
types of cancer. Tumor-derived, cell-free cir-
culating DNA extracted from the serum of 
cancer patients has been shown to contain 
cancer-associated abnormalities. The use of 
serum or plasma or even other body fluids, 
such bronchoalveolar lavage could be an al-
ternative to tissue biopsy, which is not al-
ways easy to obtain and requires an invasive 
procedure.  
We will focus in this review mostly on 
lung cancer, which is the leading cause of 
cancer-related mortality in the world, and 
one of the best-studied solid tumors in as-
pects of epigenetic diagnostic biomarkers. 
Many epigenetically modified genes have 
been implicated in lung cancer diagnosis as 
reviewed below, either as individual genes or 
as gene combinations. Some of the most 
studied genes are p16(CDKN2A), MGMT, 
RASSF1A, TERT,WT1, DAPK and DCC (Ta-
ble 1). 
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Table 1: Genes hypermethylated in lung cancer with potential to be used as early diagnosis epigenet-
ic biomarkers 
Gene Sample studied Subjects investigated 
p16 Plasma, breath, sputum 1443 
RASSF1, Bronchial washings, plasma, Sputum 1431 
TERT Bronchial washings 655 
WT1 Bronchial washings 655 
DAPK Sputum 487 
DCC Plasma 173 
KIFA Plasma 173 
 
 
Diagnostic epigenetic biomarkers in lung 
cancer 
Early in the development of epigenetics 
in a study by An et al. the hypermethylation 
of p16 was detected in plasma DNA from 
105 patients with non-small cell lung cancer 
(NSCLC) and 92 matched tumor DNA sam-
ples using a modified semi-nested methylat-
ion-specific PCR (MSP). The investigators 
showed that 73.3 % of the plasma samples 
and 79.3 % of the tumor samples presented 
with aberrant hypermethylation in the p16. 
The frequency of hypermethylation was in-
dependent of tumor stage, except for tumor 
stage I adenocarcinoma. These results sug-
gested p16 hypermethylation status as a po-
tential biomarker for lung cancer diagnosis 
(An et al., 2002). More recently, Xiao et al. 
reported similar results analyzing p16 pro-
moter hypermethylation in exhaled breath 
condensate (EBC), in patients with NSCLC, 
using 180 samples from 30 patients and 30 
healthy controls. Hypermethylation was de-
tected with a sensitivity of 86.66 % in cancer 
tissues and 40 % in EBC from the patients, 
while no normal tissue or any sample of the 
controls showed hypermethylation. (Xiao et 
al., 2014). Palmisano et al. using MSP, de-
tected aberrant methylation of both or either 
one of the p16 and O6-methyl-guanine-DNA 
methyltransferase (MGMT) promoters in 
DNA from sputum of individuals who later 
developed lung carcinoma, methylation be-
ing detectable up to 3 years before the cancer 
was diagnosed, with a specificity of 100 % 
(Palmisano et al., 2000). A combination of 
RASSF1A hypermethylation and KRAS muta-
tions, was evaluated by van der Drift et al. in 
bronchial washings of patients with suspect-
ed peripheral lung cancer and non diagnostic 
bronchoscopy. It was demonstrated that the 
combination could reduce the false negative 
or doubtful results of cytology by about 
24 %, with specificity for malignant lesion of 
100 % (van der Drift et al., 2012). Another 
novel epigenetic biomarker with high sensi-
tivity is the hypermethylation of SHOX1 
gene in bronchial washings, detected in 96 % 
of lung cancer patients even in cytologically 
negative samples, in a study of 55 lung can-
cer patients, whose matched morphologically 
normal adjacent tissues served as controls 
(Schneider et al., 2011). 
Several researchers have tried to improve 
the diagnostic utility of epigenetic biomar-
kers in lung cancer by analyzing the methyl-
ation status of multiple genes and defining 
gene promoter methylation signatures as di-
agnostic tools. Belinsky et al. analyzed the 
methylation status of three and seven genes 
in plasma and sputum, respectively, from 
women who survived lung cancer compared 
to clinically cancer-free smokers and never 
smokers (Belinsky et al., 2005). Women who 
survived lung cancer showed significantly 
higher odds ratio of having at least one hy-
permethylated gene in plasma than women 
who had never smoked. Lung cancer 
survivors also had 6.2-fold greater odds to 
present with three or more genes hyper-
methylated in sputum than smokers. The 
most commonly hypermethylated genes in 
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the sputum of lung cancer survivors com-
pared to smokers were MGMT, RASSF1A, 
DAPK, PAX5alpha. In lung cancer survivors, 
methylation of MGMT and RASSF1A was 
detected more commonly in sputum than in 
plasma, in contrast top16 (Belinsky et al., 
2005). 
In a large prospective study of a cohort 
of 1353 individuals at high risk for the 
development of lung cancer that was 
initiated in 1993 in Colorado (University of 
Colorado Cancer Center Sputum Screening 
Cohort Study), the researchers evaluated the 
hypermethylation of 14 genes in sputum of 
98 individuals who developed lung cancer 
and 92 controls (matched study participants 
who did not develop lung cancer) and 
demonstrated that six of them were 
associated with more than 50 % increased 
lung cancer risk. Moreover, the prevalence 
for methylation of gene promoters was 
inversely proportional to the time to lung 
cancer diagnosis. When three or more of 
these six genes were simultaneously 
methylated there was a 6.5-fold higher risk 
for lung cancer occurrence with a sensitivity 
and specificity of 65 % (Belinsky et al., 
2006). 
De Fraipont et al. reported results from 
an analysis of five genes methylation within 
a screening model for early diagnosis of lung 
cancer, which included computed tomogra-
phy, autofluorescent bronchoscopy, biopsies 
and bronchial lavage collection. 49 % of 
bronchial lavage of patients were positive for 
hypermethylation of p16, DAPK, MGMT, 
FHIT and APC genes. The prevalence of 
methylation was lower in patients with peri-
pheral tumors (38 %) compared to patients 
with central tumors (73 %). Based on these 
results, these investigators suggested the use 
of methylation analysis in lung cancer 
screening, especially to detect central tumors 
(de Fraipont et al., 2005). 
Another study linking epigenetic biomar-
kers with computed tomography (CT) 
evaluated aberrant methylation in a panel 
comprising DCC, KIF1A, NISCH and 
RARbeta in plasma of patients with abnormal 
findings on lung CT scan. 73 % of 70 
patients with malignant tumors demonstrated 
methylation in at least one gene, with 71 % 
specificity (P=0.001), compared to 22 % of 
those with non-cancerous abnormal CT 
findings (Ostrow et al., 2010). Detection of 
aberrant DNA methylation in the serum and 
tumor samples was examined in a study of 
22 patients with NSCLC, using methylation-
specific PCR for p16, DAPK, GSTP, MGMT. 
The majority of the patients (68 %) present-
ed aberrant methylation in tumor samples 
and 11 of 15 (73 %), presented abnormal 
methylation in the matched serum samples as 
well. Methylation was found in all tumor 
stages. None of the paired normal lung tissue 
of the these patients, nor any of the sera from 
patients whose tumors did not show 
methylation, was positive (Esteller et al., 
1999). Another 6-gene panel was evaluated 
as a diagnostic marker in plasma samples, 
tumor and normal lung tissues of 63 patients 
and 36 controls. The panel included BLU, 
CDH13, FHIT, p16, RARbeta and RASSF1A 
and showed concordance of methylation 
between tissue and plasma samples in equal 
or more than tri-quartile of the patients 
(86 %, 87 %, 80 %, 75 %, 76 %, and 84 % 
for each gene, respectively). Interestingly, 
multiple regression analysis showed an odds 
ratio of 10.204 for having lung cancer with 
p16 methylation (p=0.013) and 9.952 with 
RASSFIA methylation (p=0.019). Further-
more, detection of methylation in at least two 
of the six genes of the panel was established 
as a criterion for increased risk of lung 
cancer with a sensitivity of 75 % and a 
specificity of 82 % (Hsu et al., 2007).  
Another study proposed a panel of APC, 
RASSF1A AND p16 in bronchial aspirates. 
Performing quantitative methylation-specific 
PCR with a specificity of 99 %, researchers 
detected aberrant methylation in 63 % of 
patients with centrally located and 44 % with 
peripherally located cancers (Schmiemann et 
al., 2005). 
In a recent publication, Wrangle et al. 
describe the identification and definition of a 
3-gene panel of high value in early diagnosis 
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of NSCLC, after screening >300 candidate 
genes. The panel, which consisted of CDO1, 
HOXA1 and TAC1, was validated in two 
independent cohorts of primary NSCLC and 
was found to be 100 % specific showing no 
methylation in normal samples and 83-99 % 
sensitivity for NSCLC (Wrangle et al., 
2014). 
In 2012, Leng et al. evaluated the 
methylation of a panel of 31 genes, in 
sputum, in an expanded nested, case-control 
study from the Colorado cohort. They 
assessed the replication of the results for the 
better-performing genes in another case-
control study of asymptomatic stage I lung 
cancer patients from New Mexico. 
PAX5alpha, GATA5 and SULF2 genes 
showed the largest increase in case 
discrimination (ORs, 3.2-4.2). New Mexico 
patients with five or more genes methylated 
showed a 22-fold increase in lung cancer risk 
(Leng et al., 2012). Finally, improvement of 
diagnostic efficiency in lung cancer with 
DNA methylation biomarkers was also 
demonstrated in another study. The research-
ers evaluated ten genes as screening 
biomarkers, using qMSP, in 655 bronchial 
washings from the Liverpool Lung Project. 
The panel consisted of p16, TERT, WT1 and 
RASSF1 (sensitivity 82 %, specificity 91 %). 
They showed a marked improvement in 
screening potential than with cytology alone 
(sensitivity 43 %, specificity 100 %), 
especially in more proximal tumors and 
more advanced disease (Nikolaidis et al., 
2012). 
The above data provide compelling 
evidence that epigenetic biomarkers may 
play a significant role in improving early 
detection strategies and decreasing lung 
cancer morbidity and mortality in the near 
future. 
 
Diagnostic epigenetic biomarkers in other 
solid tumors 
Attempts have also been made to discov-
er and validate epigenetic biomarkers that 
might help in diagnosis and classification of 
several cancer types in easily accessible bio-
logical samples, so avoiding interventional 
diagnostic procedures (Chen et al., 2014; 
Koukoura et al., 2014). For example, in the 
case of bladder cancer, most studies have 
looked for such markers in urine (Eissa et al., 
2012). In one of the largest of such studies, 
Garcia-Baquero et al. evaluated the methyla-
tion of 18 tumor suppressor genes in 2 pro-
spective, independent sets of urine samples 
(training set of 120 preparations and valida-
tion set of 128) from patients with bladder 
cancer (170) and controls (78) using methyl-
ation specific multiplex ligation-dependent 
probe amplification. They found that meth-
ylation of RUNX3 and CACNA1A in the 
training set, and for RUNX3 and ID4 in the 
validation set, demonstrated the highest di-
agnostic accuracy (Garcia-Baquero et al., 
2013). However the impact of such interest-
ing findings on early diagnosis and disease 
outcome in patients with bladder cancer have 
to be proven in prospective clinical studies 
before they can be considered to be included 
in screening and/or early diagnosis strate-
gies. Relevant studies are rather less ad-
vanced in gastrointestinal cancers. In pancre-
atic cancer, researchers have used pancreatic 
juice samples to investigate potential diag-
nostic epigenetic biomarkers and provided 
some interesting results but of limited clini-
cal utility (Fukushima et al., 2003; Yoko-
yama et al., 2014). More work has been done 
in colorectal cancers by investigating stool- 
and blood-borne DNA methylation bi-
omarkers (Carmona et al., 2013; Grutzmann 
et al., 2008). Roperch et al. found that com-
bined assessment of the methylation status of 
NPY, PENK, and WIF1 in blood could stand 
as an effective screening test for colorectal 
cancer by identifying individuals who should 
go for colonoscopy (Roperch et al., 2013). 
Again, research for epigenetic diagnostic bi-
omarkers in colorectal cancer is at its early 
stages and their real clinical utility as yet un-
proven (Gyparaki et al., 2013). 
Alterations of the histone code have also 
been linked with prognosis. In particular, 
several studies have shown that global loss 
of certain post-translational modifications 
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are indicative of poor prognosis and high 
risk of recurrence post resection in prostate 
cancer and bladder cancer (Ellinger et al., 
2010; Seligson et al., 2005, 2009). 
 
EPIGENETICS IN PROGNOSTIC  
ASSESSMENT 
Solid tumors 
Since it is possible to detect epigenetic 
alterations in the blood of patients with solid 
tumors, several groups investigated whether 
aberrant DNA methylation in patient sera has 
any prognostic significance. Using Methy-
Light, a high-throughput DNA methylation 
assay, Muller et al. (2003) analyzed 39 genes 
in a gene evaluation set, consisting of 10 sera 
from metastasized patients, 26 patients with 
primary breast cancer, and 10 control 
patients. In order to determine the prognostic 
value of genes identified within this gene 
evaluation set, they analyzed pretreatment 
sera of 24 patients having had no adjuvant 
treatment (training set) to determine their 
prognostic value. The validity of their 
findings in the training set was tested using 
an independent test set consisting of 62 
patients. Five genes (ESR1, APC, HSD17B4, 
HIC1and RASSF1A) were indentified in the 
gene evaluation set, while in the training set, 
patients with serum positive for methylated 
DNA for RASSF1A and/or APC had the 
worst prognosis (P < 0.001). When analyzing 
all 86 of the investigated patients, multiariate 
analysis showed methylated RASSF1A 
and/or APC serum DNA to be independently 
associated with poor outcome, suggesting 
that RASSF1A/APC, is even more powerful 
than standard prognostic parameters (Muller 
et al., 2003).  
We recently studied NT5E (5'-nucleo-
tidase, ecto) expression and NT5E CpG 
island methylation in breast cancer cell lines 
and primary breast carcinomas (Wang et al., 
2012). We found that NT5E CpG island 
methylation was inversely associated with 
NT5E expression in breast carcinoma cell 
lines, while in clinical series, patients whose 
primary tumors had NT5E CpG island 
methylation were less likely to develop 
metastasis (P=0.003). Also, patients with 
tumors lacking detectable methylation had 
shorter disease-free survival (DFS) 
(P=0.001, HR=2.7) and overall survival (OS) 
(P=0.001, HR=3). The favorable prognostic 
value of NT5E methylation was confirmed in 
estrogen receptor negative (P=0.011) and in 
triple negative cases (P=0.004). Moreover, 
we observed a more favorable outcome to 
adjuvant chemotherapy in patients whose 
tumors were positive for NT5E CpG island 
methylation. We further used RT-PCR, 
qPCR, methylation-specific PCR and 
pyrosequencing to analyze expression and 
regulation of NT5E in malignant melanoma 
cell lines and primary and metastatic 
melanomas. We noted that NT5E mRNA is 
down-regulated by methylation-dependent 
transcriptional silencing in the melanoma 
cell lines and expression was reactivated by 
azacytidine. In clinical cases of melanoma, 
methylation in the NT5E CpG island 
occurred in both primary and metastatic 
melanomas and correlated with transcript-
ional downregulation of NT5E mRNA. 
Interestingly, primary melanomas with 
methylation in NT5E show limited metastatic 
potential or more commonly metastasize 
predominantly to nodal sites rather than 
viscera and brain (P=0.01) (Wang et al., 
2012). We also suggested recently that 
TFPI2-methylated DNA in the serum of 
patients with resected melanoma is a 
sensitive and specific biomarker of 
metastatic melanoma (Lo Nigro et al., 2013). 
We used qRT-PCR to assess TFPI2 
expression and pyrosequencing to analyze 
CpG island methylation in malignant 
melanoma cell lines, in benign nevi, in 112 
primary and metastatic melanomas, and in 
serum from 6 healthy individuals and 35 
patients: 20 patients with primary and 15 
patients with metastatic melanoma. We 
found the TFPI2 CpG island to be un-
methylated in nevi, while methylation was 
associated with metastatic melanoma. More 
importantly, circulating methylated TFPI2 
DNA was undetectable in sera from healthy 
individuals but detectable in sera from 
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patients with primary and metastatic 
melanomas. The presence of methylated 
TFPI2 DNA in serum was strongly 
associated with metastatic disease (P<0.01) 
(Lo Nigro et al., 2013). 
In a study by Philipp et al. (2012) the 
methylation status of HLTF and HPP1 was 
examined in pretherapeutic sera of patients 
with colorectal cancer (CRC) and matched 
primary tissues of stage IV patients using 
methylation-specific quantitative PCR in 
order to directly compare their prognostic 
significance with CEA, an established serum 
biomarker. OS was signigicantly shortened 
in case of methylation of HLTF or HPP1 or 
elevated levels of CEA. Multivariate analysis 
revealed that methylation of HLTF, HPP1 
and CEA >27 ng/ml were independent 
prognostic factors in stage IV. Overall, the 
presence of methylated DNA of HLTF or 
HPP1 in serum were found to be in-
dependent prognostic factors in metastasized 
CRC while the combination of any two or all 
three of these factors outperformed each 
marker on its own. The DNA methylation 
status of the p14ARF, RASSF1A and APC1A 
genes as assessed by pyrosequencing in 
tumor tissue from patients with CRC has 
been found to be an independent prognostic 
factor. In particular methylation of one or 
more of these genes was significantly 
associated with worse prognosis, independ-
ently of both tumor stage and differentiation 
(Nilsson et al., 2013). The methylation status 
of tumor suppressor candidate 3 (TUCS3) 
has been suggested to be of prognostic 
significance in ovarian cancer since it was 
found to have a significant and independent 
influence on progression-free and overall 
survival (Pils et al., 2013). 
Several efforts have been made to 
identify epigenetic biomarkers in patients 
with lung cancer. In the IFCT-0002 trial, two 
neoadjuvant regimens were compared in 528 
stages I to II NSCLC patients and biologic 
material when available from these patients 
was used in order to investigate potential 
prognostic and predictive biomarkers. Along 
with DAPK1 methylation and tumor stage, 
RASSF1A methylation further allowed the 
definition of three subgroups with strikingly 
different prognosis. Conversely, patients 
whose tumors showed RASSF1A methylation 
had significantly longer DFS following 
paclitaxel-based neoadjuvant chemotherapy 
suggesting its predictive value in stages I and 
II NSCLC (Darnton et al., 2005). The 
association of p16 methylation with both 
overall survival (OS) and disease-free 
survival (DFS) was performed in a recent 
meta-analysis in lung cancer. A total of 18 
studies containing 2432 patients were in-
cluded in the meta-analysis and results 
showed p16 methylation was an indicator of 
poor prognosis in NSCLC (Lou-Qian et al., 
2013). A DNA methylation microarray that 
analyzes 450,000 CpG sites was employed to 
study tumor DNA obtained from 444 
patients with NSCLC that included 237 stage 
I tumors. An independent cohort was used to 
validate the prognostic DNA methylation 
markers. A methylation signature of five 
genes (HIST1H4F, PCDHGB6, NPBWR1, 
ALX1, and HOXA9) that was originally 
found in the discovery cohort and further 
validated in the independent cohort was 
significantly associated with shorter RFS in 
stage I NSCLC (Sandoval et al., 2013). 
DAL-1/4.1B is a protein whose expression is 
down-regulated in lung adenocarcinoma. In a 
study by Kikuchi et al. loss of DAL-1 ex-
pression was found to be strongly correlated 
with promoter methylation in lung cancer 
cells. The majority of primary NSCLC 
tumors presented DAL-1 methylation, the 
incidence of methylation gradually increas-
ing in adenocarcinomas as they progressed 
and most importanly DFS and OS were 
significantly shorter in patients with tumors 
harboring methylated DAL-1 (Kikuchi et al., 
2005). 
The methylation of the apoptosis-related 
genes TMS1 and DAPK, was studied in 81 
primary gastric cancers using methylation-
specific PCR and their methylation status 
was compared with clinicopathological 
findings. Although no association was found 
with clinicopathological data, the OS of 
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patients with both methylated genes was 
significantly shorter compared with those 
with only one methylated gene or no 
methylated genes. The relation between 
chemosensitivity and methylation was also 
studied and it was noted that the response 
rate was lower in patients with methylation 
in either gene than in those without (Kato et 
al., 2008). 
In clear-cell renal cell carcinoma 
(CCRCC) the methylation status of tumor 
suppressor RASSF1A was assessed in 
relation to prognosis. High levels of 
methylation in the RASSF1A promoter were 
significantly more frequent in higher grades 
and in advanced stages and patients with 
high methylation levels had a significantly 
less favorable prognosis compared with 
those with low methylation levels. In 
multivariate analysis higher methylation 
levels were independently associated with a 
poor prognosis (Kawai et al., 2010). Another 
member of the Ras-association domain 
family of genes, RASSF2, when methylated, 
was found to be a strong prognostic marker 
in younger age patients with Ewing sarcoma. 
Using quantitative real-time methylation 
analysis (MethyLight) both RASSF1A and 
RASSF2 were frequently methylated in 
Ewing sarcoma tumors but only RASSF2 
methylation correlated with poor overall 
survival and this association was more 
pronounced in patients under the age of 18 
(Gharanei et al., 2013).  
In urological cancers, there is often 
down-regulation of KISS1 (a metastasis sup-
pressor gene) and RASSF1A. Bladder tumors 
were significantly associated with low KISS1 
expression due to DNA hypermethylation. 
KISS1 methylation was proportional to tu-
mor stage and grade and low KISS1 expres-
sion alone or combined with KISS1 hyper-
methylation were significantly correlated 
with poor disease specific survival. In multi-
variate analysis KISS1 transcript expression 
was an independent prognostic factor 
(p=0.017) (Cebrian et al., 2011). Similarly, 
RASSF1A was hypermethylated in CCRCC, 
proportionately to disease grade and stage, 
both significantly. High methylation levels 
also correlated with less favorable prognosis 
than low methylation levels (p=0.04) and in 
multivariate analysis, higher methylation 
levels remained an independent factor for 
poor prognosis (p=0.0053) (Kawai et al., 
2010). 
In esophageal adenocarcinoma, a tissue 
inhibitor of metalloproteinase-3 (TIMP-3) 
seems to influence tumor development, 
growth and metastasis through interactions 
with extracellular matrix metalloproteases. In 
2005, Darnton et al. studied TIMP-3 methyl-
ation, mRNA expression and protein expres-
sion. Methylation was observed in 80 % of 
Barrett esophagus samples and 90 % of ade-
nocarcinomas. Protein staining at the invad-
ing edge of EADCs was equal to, or lower 
than in normal tissues. Reduction of protein 
expression significantly correlated with dis-
ease stage (p=0.046) and predicted poor pa-
tient survival (p=0.007) (Darnton et al., 
2005). 
Kato et al. examined the methylation 
status of TMS1 and DAPK (apoptosis related 
genes) in gastric cancer and their impact on 
patients prognosis. The incidence of methyl-
ation was 32.1 % and 22.2 % (26/81 and 
18/81) respectively. The overall survival was 
significantly lower in patients who had both 
genes methylated than those who had only 
one or no gene methylated (p=0.0003) and 
this was independent of other clinico-
pathological variables. The investigators also 
examined patients who had undergone 
radical resection of the tumor and presented 
with recurrence or distal metastasis and were 
treated with 5-fluorouracil-based chemo-
therapy. In patients with either gene methyl-
ated the response rate was lower and time to 
progression was shorter than in patients 
without methylation. Comparing patients 
with both genes methylated versus either or 
no gene methylated, time to progression was 
significantly shorter (p=0.0082) while 
overall survival showed a trend (p=0.0806) 
to be shorter, as well (Kato et al., 2008). 
In medulloblastoma there is a significant 
correlation beween a regulator of neuronal 
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development, miRNA-9, low expression and 
the diagnosis of aggressive variants with 
poor outcome (Fiaschetti et al., 2014), while 
in glial cell neoplasia inhibitor of DNA 
binding/differentiation 4 (ID4) methylation 
was shown to predict a significantly more 
favorable clinical outcome (Martini et al., 
2013). 
 
Hematological malignancies 
As far as myeloid hematological malig-
nancies are concerned, a recent study, in pa-
tients from three independent large AML 
cohorts, concluded to a Hematopoetic Stem 
Cell (HSC) commitment-associated epige-
netic signature, which seems to be an inde-
pendent prognostic marker for AML 
(Bartholdy et al., 2014). In another study 
with AML or MDS patients treated with aza-
cytidine, the presence of 2 or more methylat-
ed genes prior to the treatment (p=0.022), or 
elevated white blood cell count (p=0.033), or 
anemia (p=0.029) were independent poor 
prognosticators. The presence of any of the 
above correlated significantly with shorter 
OS (Abaigar et al., 2013). On the other hand, 
in cytogenetically normal AML, hypermeth-
ylation of genes targeted by the Polycomb 
group proteins significantly and inde-
pendently correlated with better PFS and OS 
(Deneberg et al., 2011). 
Other studies have shown that epigenetic 
silencing of tumor suppressor genes, such as 
p15(INK4b) and E-cadherin (Shimamoto et 
al., 2005), or over-expression of transcription 
factors as EVI1 (Vazquez et al., 2011), sig-
nificantly correlates with poor outcome. 
Shimamoto et al. showed that promoter 
methylation of each of p15(INK4b) or E-
cadherin predicted unfavorable outcome 
(p=0.0012 and p=0.0004, respectively), en-
hancing the prognostic power when both 
promoters were methylated (Shimamoto et 
al., 2005). Vazquez et al. showed that loss of 
promoter hypermethylation and histone mod-
ifications (H3 and H4 acetylation, loss of 
H3K27 trimethylation and H3K4 trimethyla-
tion) lead to over-expression of EVI 1, which 
is a poor prognosticator in AML patients 
younger than 65 years old, whereas absence 
of EVI1 over-expression in diagnosis corre-
lated with better prognosis (Vazquez et al., 
2011). 
In 247 patients with chronic lymphocytic 
leukemia (CLL) from four independent clin-
ical studies, ZAP-70 expression was ana-
lyzed. An area in the 5’ regulatory region of 
ZAP-70 gene showed extensive variability in 
methylation in CLL samples, while in nor-
mal cells it was universally methylated. Loss 
of methylation at a specific CpG dinucleo-
tide within this region particularly affected 
transcriptional control of ZAP-70 and pre-
dicted poor prognosis with time to treatment, 
PFS and OS as outcomes (Claus et al., 
2012). 
In multiple myeloma (MM) transcrip-
tional inactivation of tumor suppressor genes 
has also been identified and associated with 
the clinical outcome. In a study, four genes 
mediating important tumor suppressive func-
tions, GPX3 (response to oxidative stress), 
RBP1 (retinoic acid signaling), SPARC (in-
teraction with the microenvironment) and 
TGFBI (response to chemotherapy) were 
shown to be epigenetically silenced through 
DNA hypermethylation. Hypermethylation 
of these genes significantly predicted shorter 
OS, independently of other known risk fac-
tors as age, adverse cytogenetics and Interna-
tional Staging System (Kaiser et al., 2013) 
Similarly, Takada et al. found FHIT gene 
lated by methylation. Although no associat-
ion between FHIT gene methylation and 
clinical variables was found, the estimated 
median survival of the methylated group was 
significantly shorter than that of the 
unmethylated group. Multivariate analysis 
revealed that FHIT methylation, elevated 
beta-2-microglobulin serum levels and ab-
sence of auto-PBSCT from treatment were 
significant and independent prognostic fac-
tors in MM (Takada et al., 2005). 
We analyzed the DNA methylation status 
of BIK (bcl2-interacting killer) gene in 40 
MM patients. BIK is a member of the BH3-
only bcl2 family of pro-apoptotic proteins. It 
has already been shown to be suppressed in 
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MM in vitro. We found 40 % of the patients 
to present with aberrant methylation in BIK 
promoter and showed that its methylation 
significantly predicted disease progression to 
relapsed/refractory myeloma (Hatzimichael 
et al., 2012). 
P15INK4b (CDKN2B) and p16INK4a 
(CDKN2A) promoter methylation has been 
implicated in the pathogenesis of MM in var-
ious studies. In a meta-analysis that included 
thirteen clinical case-control studies, which 
enrolled a total of 465 MM patients and 180 
healthy subjects, the frequencies of p15 and 
p16 promoter methylation in cancer samples 
were significantly higher than in normal 
samples. Aberrant methylation of p15 was 
significantly related to the risk of MM 
among both Caucasians and Asians whereas 
a strong positive correlation between p16 
promoter methylation and the pathogenesis 
of MM among Asians, but not among Cau-
casians was noted (Wang et al., 2014). 
 
EPIGENETICS AND TREATMENT  
OF CANCER 
One of the important aspects of epigenet-
ic marks is that they are reversible and there-
fore good targets for the development of 
novel anticancer agents. The proof-of-
concept for epigenetic therapies are the ap-
proved demethylating agents and histone 
acetylase (HDAC) inhibitors for the treat-
ment of MDS, AML and peripheral T cell 
lymphomas, respectively. Although non se-
lective, these agents have shown efficacy and 
increasingly promising results in certain pa-
tient populations. In addition inhibitors of 
sirtuins, histone acetyl transferases (HATs), 
histone methyltransferases and histone de-
methylases are also being currently investi-
gated for potency and effectiveness.  
 
DNA methyltransferase inhibitors (DNMTi) 
or hypomethylating agents (HMA) 
Aberrant DNA methylation and DNMT 
activity has been linked to leukemogenesis 
making epigenetic alterations an attractive 
target for therapy. Several data highlight the 
link between leukemogenesis and epigenet-
ics. Conditional knockout of the DNA me-
thyltransferase Dnmt1 blocked development 
of leukemia, while haploinsufficiency of 
Dnmt1 was sufficient to delay progression of 
leukemogenesis (Trowbridge et al., 2012). 
Silencing of tumor suppressor genes by 
DNA hypermethylation may also contribute 
to leukemogenesis, whereas several muta-
tions affecting epigenetic regulators and 
therefore epigenetic modifications, such as 
DNMT3A might also play a role (Renneville 
et al., 2012).  
HMA that are currently in clinical use are 
i) azacytidine that is FDA approved for all 
subtypes of myelodysplastic syndromes 
(MDS) and EMA approved for high risk 
MDS, low blast count (20-30 %) acute mye-
loid leukemia (AML) and chronic myelo-
monocytic leukemia (CMML) and ii) decita-
bine that is FDA approved for de novo and 
secondary MDS of all FAB subtypes and 
EMA approved for AML patients aged >65 
years who are not candidates for standard 
induction chemotherapy. 
Azacytidine is an analogue of cytidine 
that cannot be methylated in the 5’ position, 
since it carries nitrogen and not a carbon. It 
is incorporated into both DNA and RNA 
during cell division. Azacytidine replaces 
cytidine in the DNA and after several cycles 
of treatment depletes cancer cells of DNMTs 
(Derissen et al., 2013). Decitabine, first syn-
thesized in the early 1960s, is an analogue of 
the natural nucleoside 2’-deoxycytidine. It 
also inhibits DNA methyltransferase activity 
following phosphorylation and can only be 
incorporated into DNA (Gore et al., 2006). 
Mechanisms other than cytosine demethyla-
tion have been proposed for both azacytidine 
and decitabine. Decitabine induces apoptosis 
followed by activation of caspases in AML 
cells through intracellular reactive oxygen 
species generation (Fandy et al., 2014, Shin 
et al., 2012) 
The use of azacytidine has changed the 
natural history of high risk MDS/low blast 
count AML and is the first and only drug 
that leads to an increase in overall survival 
(OS) with a manageable toxicity profile 
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(Fenaux et al., 2009b). Decitabine has shown 
efficacy in AML, however with no benefit in 
OS (Kantarjian et al., 2012). Both drugs are 
non-selective and yield global changes in 
DNA methylation. It is still uncertain wheth-
er their efficacy is linked to hypomethylation 
and re-expression of genes, or due to direct 
DNA damage or both and data correlating 
DNA methylation reversal and clinical re-
sponse are conflicting. 
 
Challenges for HMA 
Although azacytidine and decitabine re-
present the most active single agents for un-
selected MDS patients, only about 50 % re-
spond (Fenaux et al., 2009a), complete re-
sponses develop in less than 20 % of patients 
while the median duration of response re-
mains under two years. Unfortunately the 
outcome after failure is poor (Prebet et al., 
2011). The reasons why patients do not re-
spond in the first place or lose their response 
while on treatment remain unknown. Several 
researchers have proposed that loss of re-
sponse to azacytidine does not preclude re-
sponse to decitabine and vice versa, so they 
suggest switching hypomethylating agent 
when loss of response is observed. Another 
key issue is cellular uptake. In the case of 
azacytidine, it has been observed that its up-
take depends on variably expressed nucleo-
side transporters and that its delivery by 
elaidic acid esterification can markedly in-
crease its anticancer activity (Shishodia et 
al., 2005).  
Another challenge regarding the use of 
HMA is the identification of markers that 
could predict response to this type of treat-
ment. Several reports have addressed this 
issue. Mutations in TET2 and a favorable 
cytogenetic risk have been associated with a 
favorable response of patients with high risk 
MDS and low blast count AML (Itzykson et 
al., 2011), whereas mutations in TP53 have 
been related to poor response to azacytine 
(Kulasekararaj et al., 2013).  
One way to partly overcome these chal-
lenges and improve responses is to use HMA 
in combination with other drugs. Several 
combinations have already entered the clini-
cal trial setting such as the combination of 
HMA with HDACi and the combination of 
HMA with the thrombopoietin mimetic ro-
miplostim and results are awaited. 
Several HMA under clinical develop-
ment have shown antiproliferative activity in 
cell lines but have not yet entered the clinical 
trial setting. Zebularine is a chemically sta-
ble cytidine analog and the first oral demeth-
ylating agent (Cheng et al., 2003). A quino-
lone-based compound, named SGI-1027 has 
been shown to inhibit DNMT1, DNMT3A 
and DNMT3B, leading to re-expression of 
silenced tumor suppressor genes without 
significant toxicity in cell lines (Datta et al., 
2009). 
	
Histone deacetylase inhibitors (HDACi) 
There are four chemically distinct classes 
of HDACi: short fatty chains (eg valproate), 
cyclic peptides (eg romidepsin), hydroxamic 
acids (vorinostat, panobinostat, belinostat) 
and benzamide derivatives (entinostat). It is 
worth mentioning that the discovery of 
HDACi actually preceded the discovery of 
HDACs. Sodium butyrate was the first 
HDACi found to induce acetylation (Riggs et 
al., 1977) while later trichostatin, currently 
used in in vitro experiments, and valproic 
acid were identified. Valproic acid, a widely 
used antiseizure agent, has been adminis-
tered in combination with HMA and/or 
chemotherapy in hematological malignancies 
(Raffoux et al., 2010). 
An increasing number of HDACi are be-
ing developed and tested in phase II-III clini-
cal trials, while two of them, vorinostat and 
romidepsin have received FDA and EMA 
approval (Prince et al., 2009). In particular, 
vorinostat has received FDA approval for the 
treatment of cutaneous T cell lymphoma 
(CTCL) (Duvic et al., 2007) following two 
systemic therapies, while romidepsin for 
both CTCL and peripheral T cell lymphoma 
(PTCL) as second line treatment (Piekarz et 
al., 2011; Whittaker et al., 2010).  
Vorinostat is the first orally bioavailable 
HDAC inhibitor approved by FDA in 2006, 
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for the treatment of cutaneous manifestations 
in patients with cutaneous T-cell lymphoma 
who have progressive, persistent or recurrent 
disease on or following two systemic thera-
pies (Kavanaugh et al., 2010, Mann et al., 
2007). It is, however, inactive in relapsed 
diffuse large-B-cell lymphoma (Crump et al., 
2008) and attempts to increase its activity 
when combined with lenalidomide, have 
failed (Hopfinger et al., 2014). In other clini-
cal settings, vorinostat has shown activity in 
Polycythemia Vera and other JAK2V617F-
associated Philadelphia chromosome-nega-
tive myeloproliferative neoplasms (Akada et 
al., 2012; Andersen et al., 2013), in relapsed 
or refractory Follicular Lymphoma (Ogura et 
al., 2014), in Acute Myeloid Leukemia in 
combination with idarubicin and cytarabine 
achieving an ORR of 85 % (Garcia-Manero 
et al., 2012) and in multiple myeloma in 
combination with lenalidomide and dexame-
thasone (Siegel et al., 2014a). However in a 
phase III trial, the combination of vorinostat 
and bortezomib failed to produce a clinically 
relevant difference in PFS relative to borte-
zomib and placebo although the reason is not 
clear (Dimopoulos et al., 2013). 
Vorinostat has also been investigated in 
solid tumors. In breast cancer the combina-
tion of vorinostat with tamoxifen has been 
investigated in patients with ER-positive 
metastatic breast cancer progressing on en-
docrine therapy and demonstrated encourag-
ing activity in reversing hormone resistance 
(Munster et al., 2011). On the other side it 
has shown modest or no activity in glioblas-
toma, melanoma, non-small cell lung cancer, 
and head and neck cancers (Blumenschein et 
al., 2008; Galanis et al., 2009; Haas et al., 
2014; Hoang et al., 2014).  
A variety of trials have been conducted 
using romidepsin in patients with malignan-
cies such as pancreatic cancer, ovarian can-
cer, melanoma, prostate cancer and MM, but 
the most striking results were noted in pa-
tients CTCL and PTCL, leading to its ap-
proval. Romidepsin was evaluated in two 
multicenter, single arm studies in patients 
with CTCL and in both studies patients 
could be treated until disease progression. It 
has not been compared to other treatments in 
a randomized fashion. ORR ranged from 25 
to 38 % and median time to CR was 6 
months (Piekarz et al., 2009). 
Panobinostat (LBH-589) is a potent, oral 
pan HDAC inhibitor targeting the epigenetic 
regulation of multiple oncogenic pathways, 
with development focused on hematological 
malignancies (Li et al., 2014; Rhodes et al., 
2014; Tan et al., 2014). Specifically it has 
shown activity in refractory/relapsed T cell 
lymphomas, Hodgkin’s Lymphoma, Wal-
denstrom macroglobulinemia and in multiple 
myeloma in combination with bortezomib 
and dexamethasone (Duvic et al., 2013; Ellis 
et al., 2008; Ghobrial et al., 2013; Richard-
son et al., 2013; Younes et al., 2012). Most 
recently, panobinostat in combination with 
bortezomib and dexamethasone met the pri-
mary endpoint of phase III trial PANO-
RAMA 1, of significantly extending progres-
sion-free survival in patients with relapsed or 
refractory multiple myeloma when compared 
to bortezomib plus dexamethasone alone 
(Richardson et al., 2014). Based on these re-
sults presented at ASCO 2014, FDA granted 
panobinostat “Priority Review” designation 
as a new drug for multiple myeloma (May 
2014). 
Belinostat (PXD 101) is a novel inhibitor 
of enzymatic activity of class 1 and class 2 
HDACs in late stage of clinical development 
for PTCL. Two phase II studies with belino-
stat given intravenously in the relapsed/re-
fractory PTCL setting produced approxi-
mately 25 % overall response rate with a fa-
vorable toxicity profile. These findings have 
led to a request for accelerated FDA approv-
al of belinostat in this setting (McDermott 
and Jimeno, 2014) Following that, FDA ap-
proved belinostat (BeleodaqTM) on July 03, 
2014 for the treatment of relapsed or refrac-
tory peripheral T-cell lymphoma. In other 
tumors, belinostat has shown only minimal 
activity in AML (Kirschbaum et al., 2014) 
and in platinum resistant epithelial ovarian 
cancer (Mackay et al., 2010), and is ineffec-
tive in MDS (Cashen et al., 2012) in malig-
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nant mesothelioma (Ramalingam et al., 
2009), in recurrent thymic carcinomas 
(Giaccone et al., 2011) and in unresectable 
hepatocellular carcinoma (Yeo et al., 2012).  
In NSCLC a number of HDACi such as 
entinostat (in combination with erlotinob), 
vorinostat and CI-994 are in early stages of 
clinical development and first results have 
been reported (Gridelli et al., 2008; Witta et 
al., 2012). However, it seems that we may 
need rational combinations of HDACi with 
other cytotoxic agents in order to counterbal-
ance the inherent potential of these com-
pounds to reactivate tumor-progression 
genes (Lin et al., 2012). 
Second generation HDACi, such as 
ACY-1215 are more selective and it would 
be interesting to see the efficacy and safety 
profile of such compounds. ACY-115 is cur-
rently being tested in a phase I/II study as 
monotherapy and in combination with borte-
zomib and dexamethasone in relapsed/re-
fractory MM (Santo et al., 2012). 
As we have mentioned previously, 
HDACi do not only deacetylate histones, but 
also other proteins such as transcription fac-
tors or even products of oncogenes or TSG 
involved in oncogenesis. This may partly 
explain some off-target effects or disappoint-
ing results in efficacy (Hatzimichael and 
Crook, 2013). 
 
Histone methyltransferases (HMT) and 
Histone methyltransferase inhibitors 
(HMTi) 
Other than DOT1L (KMT4), all lysine 
methyltransferases contain the conserved 
SET (Suppressor of variegation, Enhancer of 
zeste, and Trithorax) domain. Recently, the 
notion that demethylation occurs only on 
synthesis of new histones was over-turned 
with the discovery of enzymes that convert 
arginine to citrulline, to remove arginine 
methylation, and lysine demethylases, in-
cluding LSD1 (KDM1) and the Jumonji C 
family (Johansson et al., 2014; Li et al., 
2012; Wang et al., 2009). 
HMTi are at their very early phases of 
development and include chaetocin, 3-
Deazaneplanocin A (DZNep) and BIX-
01294. Chaetocin, a fungal mycotoxin, is a 
non specific inhibitor of lysine methyltrans-
ferases (Cherblanc et al., 2013) that has 
shown antimyeloma activity (Isham et al., 
2007). DZNep promotes the depletion of the 
polycomb-repressive complex-2 proteins, 
such as EZH2 and inhibits methylation of 
H3K27 (Tan et al., 2007). Moreover it has 
also a potential therapeutic effect on Acute 
Myeloid Leukemia by disrupting polycomb-
repressive complex 2 (PRC2) and by target-
ing MLL fusion leukemia stem cells (Ueda 
et al., 2014; Zhou et al., 2011). BIX-01294, a 
specific inhibitor of euchromatic HMT2 has 
recently been shown to sensitize human 
promyelocytic leukemia HL-60 and NB4 
cells to growth inhibition and differentiation 
(Savickiene et al., 2014). Moreover chemical 
modifications of this molecule were shown 
to gain selective anti-DNA methyltransferase 
3A activity (Rotili et al., 2014). Finally an-
other class of emerging EZH2 histone me-
thyltransferase inhibitors, at their very early 
stages of investigation is tanshindiols (Woo 
et al., 2014). 
 
Histone acetyltransferase inhibitors (HATi) 
Histone acetylation is a reversible mech-
anism that plays a critical role in eukaryotic 
genes activation/deactivation and abnormal 
activation of histone acetyltransferases is 
implicated in several cancers (Malatesta et 
al., 2013). This knowledge led to the consid-
eration of discovering and developing HAT 
inhibitors as another epigenetic treatment 
approach of cancer (Carradori et al., 2014; 
Secci et al., 2014). The discovery and devel-
opment of HAT inhibitors is in their very 
early steps. So far three phytochemical HAT 
inhibitors have been described: garcinol, an-
acardic acid and curcumin. The latter is an 
EP300- and CREBBP-specific inhibitor that 
has been shown to inhibit cyclin D1 and nu-
clear factor-kB (Mukhopadhyay et al., 2002; 
Shishodia et al., 2005). 
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CONCLUSIONS 
Here we have reviewed some examples 
of the new prognostic and therapeutic appli-
cations of epigenetics in solid tumor and 
hematological malignancy. The rapidly 
evolving epigenetic landscape has already 
generated clinically useful biomarkers and 
active anti-cancer drugs. Generation of can-
cer signatures from multiple tumor sites in 
large-scale studies will undoubtedly result in 
the development of further effective pharma-
cological agents to treat cancer and new pre-
dictive and prognostic biomarkers to inform 
management of the disease. There is now 
every reason to believe that the long held 
promise of epigenetics is about to be fully 
realized. 
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